Tirzepatide and retatrutide represent two generations of the same broader idea — that hitting multiple metabolic receptor pathways simultaneously outperforms single-pathway GLP-1 agonists like semaglutide. Retatrutide adds a third receptor target on top of what tirzepatide already does. Here’s what that actually changes.
Receptor Targets
| Tirzepatide | Retatrutide | |
|---|---|---|
| GLP-1 receptor | Yes | Yes |
| GIP receptor | Yes | Yes |
| Glucagon receptor | No | Yes — the differentiating third mechanism |
What the Glucagon Receptor Adds
Glucagon receptor agonism increases energy expenditure and hepatic fat oxidation in addition to the appetite-suppression effects shared with the other two pathways. This is the mechanistic basis for retatrutide’s research reputation as the current ceiling for pharmacologic weight loss — it’s not just suppressing intake, it’s theoretically increasing output too.
Where the Data Currently Stands
Retatrutide’s TRIUMPH-1 trial data reported average body weight loss in the high-20s percent range at 80 weeks, with a meaningful share of patients exceeding 30% loss, and extension data showing continued loss without an apparent plateau at 104 weeks. Tirzepatide has a longer track record and a larger real-world evidence base simply by virtue of being further along in its approval and use timeline. Retatrutide remains investigational, with an NDA filing anticipated but not yet approved as of mid-2026.
Sourcing
Retatrutide is research-use only. Compounded tirzepatide access runs through licensed telehealth and compounding pathways rather than research vendors — see our provider directory for that route.